Edition:
United States

Biotechnology & Medical Research

Page 2

Alnylam Pharmaceuticals prices public offering of common stock

Wednesday, 24 May 2017 09:00am EDT

May 24 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam Pharmaceuticals prices public offering of common stock.Says public offering of 5.00 million common shares priced at $71.87 per share.

Albireo prices $45.1 million public offering of common stock

Wednesday, 24 May 2017 08:39am EDT

May 24 (Reuters) - Albireo Pharma Inc : :Albireo prices $45.1 million public offering of common stock.Says public offering of 2.20 million common shares priced at $20.50per share.

Glycomimetics announces pricing of public offering of common stock

Wednesday, 24 May 2017 08:00am EDT

May 24 (Reuters) - Glycomimetics Inc :Glycomimetics announces pricing of public offering of common stock.Says public offering of 7.00 million common shares priced at $11.50per share.

Inovio's HIV vaccine produces nearly 100 pct immune response rates in clinical study

Wednesday, 24 May 2017 08:00am EDT

May 24 (Reuters) - Inovio Pharmaceuticals Inc :Inovio HIV vaccine elicits nearly 100% immune response rates in a clinical study.Inovio Pharmaceuticals Inc - amongst evaluated participants receiving PENNVAX-GP and IL-12 via im vaccination, 27 of 27 demonstrated a cellular response.

Glycomimetics Inc terminates sales agreement with Cowen and Company

Wednesday, 24 May 2017 07:25am EDT

May 24 (Reuters) - Glycomimetics Inc :Glycomimetics Inc - co terminated its sales agreement, dated March 1, 2016, with Cowen and Company.

Mabvax Therapeutics Q1 loss per share $0.85

Wednesday, 24 May 2017 07:05am EDT

May 24 (Reuters) - Mabvax Therapeutics Holdings Inc :Mabvax Therapeutics reports first quarter 2017 operational and financial results.Q1 loss per share $0.85.

Karessa Pharma Holding signs agreement with PCG Clinical Services

Wednesday, 24 May 2017 03:00am EDT

May 24 (Reuters) - KARESSA PHARMA HOLDING AB (PUBL) ::KARESSA HAS SIGNED AN AGREEMENT WITH PCG CLINICAL SERVICES AB TO CONDUCT CLINICAL TRIALS IN THE K-03 PROJECT.

Intervacc Q1 EBITDA loss SEK 0.4 million

Wednesday, 24 May 2017 02:54am EDT

May 24 (Reuters) - INTERVACC AB :Q1 NET REVENUE SEK 11.3 MILLION VERSUS SEK 6.1 MILLION YEAR AGO.Q1 EBITDA LOSS SEK 0.4 MILLION VERSUS LOSS SEK 1.3 MILLION YEAR AGO.

Nordic Nanovector Q1 comprehensive loss NOK 55.8 million

Wednesday, 24 May 2017 01:00am EDT

May 24 (Reuters) - NORDIC NANOVECTOR ASA :REVENUES IN Q1 2017 AMOUNTED TO NOK 0.078 MILLION (NOK 0.078 MILLION).COMPREHENSIVE LOSS FOR Q1 AMOUNTED TO NOK 55.8 MILLION (LOSS OF NOK 64.1 MILLION).TOTAL OPERATING EXPENSES FOR Q1 WERE NOK 65.8 MILLION (NOK 52.7 MILLION).CURRENT CASH RESOURCES ARE EXPECTED TO BE SUFFICIENT TO TAKE COMPANY BEYOND A FIRST REGULATORY SUBMISSION FOR BETALUTIN® IN FL IN FIRST HALF OF 2019.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary